https://orcid.org/0000-0002-0289-5456
Key Points
The deficiency of pseudouridine in mt-tRNAs due to PUS1 mutation contributes to impaired mitochondrial function and anemia in a patient with MLASA.
The mTOR inhibitor rapamycin shows promise as a therapeutic approach for MLASA-associated anemia.
Abstract
Pseudouridine is the most prevalent RNA modification, and its aberrant function is implicated in various human diseases. However, the specific impact of pseudouridylation on hematopoiesis remains poorly understood. Here, we investigated the role of transfer RNA (tRNA) pseudouridylation in erythropoiesis and its association with mitochondrial myopathy, lactic acidosis, and sideroblastic anemia syndrome (MLASA) pathogenesis. By using patient-specific induced pluripotent stem cells (iPSCs) carrying a genetic pseudouridine synthase 1 (PUS1) mutation and a corresponding mutant mouse model, we demonstrated impaired erythropoiesis in MLASA-iPSCs and anemia in the MLASA mouse model. Both MLASA-iPSCs and mouse erythroblasts exhibited compromised mitochondrial function and impaired protein synthesis. Mechanistically, we revealed that PUS1 deficiency resulted in reduced mitochondrial tRNA levels because of pseudouridylation loss, leading to aberrant mitochondrial translation. Screening of mitochondrial supplements aimed at enhancing respiration or heme synthesis showed limited effect in promoting erythroid differentiation. Interestingly, the mammalian target of rapamycin (mTOR) inhibitor rapamycin facilitated erythroid differentiation in MLASA-iPSCs by suppressing mTOR signaling and protein synthesis, and consistent results were observed in the MLASA mouse model. Importantly, rapamycin treatment partially ameliorated anemia phenotypes in a patient with MLASA. Our findings provide novel insights into the crucial role of mitochondrial tRNA pseudouridylation in governing erythropoiesis and present potential therapeutic strategies for patients with anemia facing challenges related to protein translation.
References
1.
Cohn
WE
. Pseudouridine, a carbon-carbon linked ribonucleoside in ribonucleic acids: isolation, structure, and chemical characteristics
. J Biol Chem
. 1960
;235(5)
:1488
-1498
.2.
Carlile
TM
, Martinez
NM
, Schaening
C
, et al. mRNA structure determines modification by pseudouridine synthase 1
. Nat Chem Biol
. 2019
;15
(10
):966
-974
.3.
Song
J
, Zhuang
Y
, Zhu
C
, et al. Differential roles of human PUS10 in miRNA processing and tRNA pseudouridylation
. Nat Chem Biol
. 2020
;16
(2
):160
-169
.4.
Li
X
, Xiong
X
, Yi
C
. Epitranscriptome sequencing technologies: decoding RNA modifications
. Nat Methods
. 2016
;14
(1
):23
-31
.5.
Cerneckis
J
, Cui
Q
, He
C
, Yi
C
, Shi
Y
. Decoding pseudouridine: an emerging target for therapeutic development
. Trends Pharmacol Sci
. 2022
;43
(6
):522
-535
.6.
Guzzi
N
, Muthukumar
S
, Ciesla
M
, et al. Pseudouridine-modified tRNA fragments repress aberrant protein synthesis and predict leukaemic progression in myelodysplastic syndrome
. Nat Cell Biol
. 2022
;24
(3
):299
-306
.7.
Guzzi
N
, Ciesla
M
, Ngoc
PCT
, et al. Pseudouridylation of tRNA derived fragments steers translational control in stem cells
. Cell
. 2018
;173
(5
):1204
-1216.e26
.8.
Cui
Q
, Yin
K
, Zhang
X
, et al. Targeting PUS7 suppresses tRNA pseudouridylation and glioblastoma tumorigenesis
. Nat Cancer
. 2021
;2
(9
):932
-949
.9.
An
X
, Schulz
VP
, Li
J
, et al. Global transcriptome analyses of human and murine terminal erythroid differentiation
. Blood
. 2014
;123
(22
):3466
-3477
.10.
Ducamp
S
, Fleming
MD
. The molecular genetics of sideroblastic anemia
. Blood
. 2019
;133
(1
):59
-69
.11.
Burrage
LC
, Tang
S
, Wang
J
, et al. Mitochondrial myopathy, lactic acidosis, and sideroblastic anemia (MLASA) plus associated with a novel de novo mutation (m.8969G>A) in the mitochondrial encoded ATP6 gene
. Mol Genet Metab
. 2014
;113
(3
):207
-212
.12.
Zhang
Y
, Zhang
J
, An
W
, et al. Intron 1 GATA site enhances ALAS2 expression indispensably during erythroid differentiation
. Nucleic Acids Res
. 2017
;45
(2
):657
-671
.13.
Tesarova
M
, Vondrackova
A
, Stufkova
H
, et al. Sideroblastic anemia associated with multisystem mitochondrial disorders
. Pediatr Blood Cancer
. 2019
;66
(4
):e27591
.14.
Bykhovskaya
Y
, Casas
K
, Mengesha
E
, Inbal
A
, Fischel-Ghodsian
N
. Missense mutation in pseudouridine synthase 1 (PUS1) causes mitochondrial myopathy and sideroblastic anemia (MLASA)
. Am J Hum Genet
. 2004
;74
(6
):1303
-1308
.15.
Fernandez-Vizarra
E
, Berardinelli
A
, Valente
L
, Tiranti
V
, Zeviani
M
. Nonsense mutation in pseudouridylate synthase 1 (PUS1) in two brothers affected by myopathy, lactic acidosis and sideroblastic anemia (MLASA)
. BMJ Case Rep
. 2009
;2009
:bcr05.2009.1889
.16.
Finsterer
J
. Comment on: sideroblastic anemia associated with multisystem mitochondrial disorders: the phenotypic spectrum of PUS1 and COX10 variants and mtDNA deletions needs to be prospectively assessed
. Pediatr Blood Cancer
. 2019
;66
(11
):e27945
.17.
Zeharia
A
, Fischel-Ghodsian
N
, Casas
K
, et al. Mitochondrial myopathy, sideroblastic anemia, and lactic acidosis: an autosomal recessive syndrome in Persian Jews caused by a mutation in the PUS1 gene
. J Child Neurol
. 2005
;20
(5
):449
-452
.18.
Oncul
U
, Unal-Ince
E
, Kuloglu
Z
, Teber-Tiras
S
, Kaygusuz
G
, Eminoglu
FT
. A novel PUS1 mutation in 2 siblings with MLASA syndrome: a review of the literature
. J Pediatr Hematol Oncol
. 2021
;43
(4
):e592
-e595
.19.
Fernandez-Vizarra
E
, Berardinelli
A
, Valente
L
, Tiranti
V
, Zeviani
M
. Nonsense mutation in pseudouridylate synthase 1 (PUS1) in two brothers affected by myopathy, lactic acidosis and sideroblastic anemia (MLASA)
. J Med Genet
. 2007
;44
(3
):173
-180
.20.
Metodiev
MD
, Assouline
Z
, Landrieu
P
, et al. Unusual clinical expression and long survival of a pseudouridylate synthase (PUS1) mutation into adulthood
. Eur J Hum Genet
. 2015
;23
(6
):880
-882
.21.
Cao
M
, Dona
M
, Valentino
ML
, et al. Clinical and molecular study in a long-surviving patient with MLASA syndrome due to novel PUS1 mutations
. Neurogenetics
. 2016
;17
(1
):65
-70
.22.
Kasapkara
CS
, Tumer
L
, Zanetti
N
, Ezgu
F
, Lamantea
E
, Zeviani
M
. A myopathy, lactic acidosis, sideroblastic anemia (MLASA) case due to a novel PUS1 mutation
. Turk J Haematol
. 2017
;34
(4
):376
-377
.23.
Patton
JR
, Bykhovskaya
Y
, Mengesha
E
, Bertolotto
C
, Fischel-Ghodsian
N
. Mitochondrial myopathy and sideroblastic anemia (MLASA): missense mutation in the pseudouridine synthase 1 (PUS1) gene is associated with the loss of tRNA pseudouridylation
. J Biol Chem
. 2005
;280
(20
):19823
-19828
.24.
Shi
D
, Wang
B
, Li
H
, et al. Pseudouridine synthase 1 regulates erythropoiesis via transfer RNAs pseudouridylation and cytoplasmic translation
. iScience
. 2024
;27
(3
):109265
.25.
Xu
C
, He
J
, Wang
H
, et al. Single-cell transcriptomic analysis identifies an immune-prone population in erythroid precursors during human ontogenesis
. Nat Immunol
. 2022
;23
(7
):1109
-1120
.26.
Zhu
H
, Kaufman
DS
. An improved method to produce clinical-scale natural killer cells from human pluripotent stem cells
. Methods Mol Biol
. 2019
;2048
:107
-119
.27.
Borchardt
EK
, Martinez
NM
, Gilbert
WV
. Regulation and function of RNA pseudouridylation in human cells
. Annu Rev Genet
. 2020
;54
:309
-336
.28.
Couvillion
MT
, Soto
IC
, Shipkovenska
G
, Churchman
LS
. Synchronized mitochondrial and cytosolic translation programs
. Nature
. 2016
;533
(7604
):499
-503
.29.
Xiao
Z
, Zou
Q
, Liu
Y
, Yang
X
. Genome-wide assessment of differential translations with ribosome profiling data
. Nat Commun
. 2016
;7
:11194
.30.
Lichtenstein
DA
, Crispin
AW
, Sendamarai
AK
, et al. A recurring mutation in the respiratory complex 1 protein NDUFB11 is responsible for a novel form of X-linked sideroblastic anemia
. Blood
. 2016
;128
(15
):1913
-1917
.31.
Zhang
H
, Ryu
D
, Wu
Y
, et al. NAD⁺ repletion improves mitochondrial and stem cell function and enhances life span in mice
. Science
. 2016
;352
(6292
):1436
-1443
.32.
Li
C
, Wu
B
, Li
Y
, et al. Amino acid catabolism regulates hematopoietic stem cell proteostasis via a GCN2-eIF2alpha axis
. Cell Stem Cell
. 2022
;29
(7
):1119
-1134.e1117
.33.
Rossmann
MP
, Hoi
K
, Chan
V
, et al. Cell-specific transcriptional control of mitochondrial metabolism by TIF1γ drives erythropoiesis
. Science
. 2021
;372
(6543
):716
-721
.34.
Thoreen
CC
, Chantranupong
L
, Keys
HR
, Wang
T
, Gray
NS
, Sabatini
DM
. A unifying model for mTORC1-mediated regulation of mRNA translation
. Nature
. 2012
;485
(7396
):109
-113
.35.
Morita
M
, Gravel
SP
, Chénard
V
, et al. mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation
. Cell Metab
. 2013
;18
(5
):698
-711
.36.
Mangum
JE
, Hardee
JP
, Fix
DK
, et al. Pseudouridine synthase 1 deficient mice, a model for mitochondrial myopathy with sideroblastic anemia, exhibit muscle morphology and physiology alterations
. Sci Rep
. 2016
;6
:26202
.37.
Schneider
RK
, Schenone
M
, Ferreira
MV
, et al. Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9
. Nat Med
. 2016
;22
(3
):288
-297
.38.
Knight
ZA
, Schmidt
SF
, Birsoy
K
, Tan
K
, Friedman
JM
. A critical role for mTORC1 in erythropoiesis and anemia
. Elife
. 2014
;3
:e01913
.39.
Shah
PR
, Kute
VB
, Patel
HV
, Trivedi
HL
. Therapeutic drug monitoring of sirolimus
. Clinical Queries: Nephrology
. 2015
;4
(3-4
):44
-49
.40.
Vissers
C
, Sinha
A
, Ming
GL
, Song
H
. The epitranscriptome in stem cell biology and neural development
. Neurobiol Dis
. 2020
;146
:105139
.41.
Suzuki
T
. The expanding world of tRNA modifications and their disease relevance
. Nat Rev Mol Cell Biol
. 2021
;22
(6
):375
-392
.42.
Liu
X
, Zhang
Y
, Ni
M
, et al. Regulation of mitochondrial biogenesis in erythropoiesis by mTORC1-mediated protein translation
. Nat Cell Biol
. 2017
;19
(6
):626
-638
.43.
Payne
EM
, Virgilio
M
, Narla
A
, et al. L-Leucine improves the anemia and developmental defects associated with Diamond-Blackfan anemia and del(5q) MDS by activating the mTOR pathway
. Blood
. 2012
;120
(11
):2214
-2224
.44.
Gonzalez-Menendez
P
, Romano
M
, Yan
H
, et al. An IDH1-vitamin C crosstalk drives human erythroid development by inhibiting pro-oxidant mitochondrial metabolism
. Cell Rep
. 2021
;34
(5
):108723
.45.
Bachmeyer
C
, Ferroir
JP
, Eymard
B
, Maïer-Redelsperger
M
, Lebre
AS
, Girot
R
. Coenzyme Q is effective on anemia in a patient with sideroblastic anemia and mitochondrial myopathy
. Blood
. 2010
;116
(18
):3681
-3682
.46.
Abu-Zeinah
G
, DeSancho
MT
. Understanding sideroblastic anemia: an overview of genetics, epidemiology, pathophysiology and current therapeutic options
. J Blood Med
. 2020
;11
:305
-318
.47.
Huang
Y
, Chen
M
, Yang
C
, Ruan
J
, Wang
S
, Han
B
. Sirolimus is effective for refractory/relapsed/intolerant acquired pure red cell aplasia: results of a prospective single-institutional trial
. Leukemia
. 2022
;36
(5
):1351
-1360
.48.
Park
JA
, Lee
HH
, Kwon
HS
, Baik
CR
, Song
SA
, Lee
JN
. Sirolimus for refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: a case report and literature review of the treatment of post-transplant autoimmune hemolytic anemia
. Transfus Med Rev
. 2016
;30
(1
):6
-14
.© 2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
2024
You do not currently have access to this content.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal